These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1621752)

  • 1. Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis.
    Hyslop DL; Bischoff W
    Am J Med; 1992 Jun; 92(6A):86S-94S. PubMed ID: 1621752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin-structure infections in an adult population.
    McCarty J; Ruoff GE; Jacobson KD
    Am J Med; 1992 Jun; 92(6A):80S-85S. PubMed ID: 1621751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic therapy for urinary tract infections.
    Iravani A; Bischoff W
    Am J Med; 1992 Jun; 92(6A):95S-100S. PubMed ID: 1621753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loracarbef (LY163892) versus cefaclor in the treatment of acute bacterial bronchitis.
    Dere WH; Farlow D; Therasse DG; Ruoff GE
    Clin Ther; 1992; 14(1):41-53. PubMed ID: 1576625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loracarbef (LY163892) in the treatment of acute exacerbations of chronic bronchitis: results of U.S. and European comparative clinical trials.
    Zeckel ML
    Am J Med; 1992 Jun; 92(6A):58S-64S. PubMed ID: 1621746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loracarbef versus cefaclor in the treatment of cystitis and asymptomatic bacteriuria.
    Iravani A
    Clin Ther; 1992; 14(1):54-63. PubMed ID: 1576626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loracarbef versus cefaclor in the treatment of urinary tract infections in women.
    Iravani A
    Antimicrob Agents Chemother; 1991 Apr; 35(4):750-2. PubMed ID: 2069382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loracarbef vs. cefaclor in pediatric skin and skin structure infections.
    Hanfling MJ; Hausinger SA; Squires J
    Pediatr Infect Dis J; 1992 Aug; 11(8 Suppl):S27-30. PubMed ID: 1513609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis.
    Cattrall JWS; Robinson AV; Kirby A
    Eur J Clin Microbiol Infect Dis; 2018 Dec; 37(12):2285-2291. PubMed ID: 30191339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loracarbef versus penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis in an adult population.
    McCarty J
    Am J Med; 1992 Jun; 92(6A):74S-79S. PubMed ID: 1621750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.
    Müller O; Wettich K
    Infection; 1992; 20(3):176-82. PubMed ID: 1463527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection.
    Leigh AP; Nemeth MA; Keyserling CH; Hotary LH; Tack KJ
    Clin Ther; 2000 Jul; 22(7):818-25. PubMed ID: 10945508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zeckel ML; Jacobson KD; Guerra FJ; Therasse DG; Farlow D
    Clin Ther; 1992; 14(2):214-29. PubMed ID: 1611645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections.
    Therasse DG
    Am J Med; 1992 Jun; 92(6A):20S-25S. PubMed ID: 1621742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loracarbef versus penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis in adults.
    McCarty J; Hernon Y; Linn L; Therasse DG; Molina A; Bleile N
    Clin Ther; 1992; 14(1):30-40. PubMed ID: 1576624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis.
    Sandberg T; Englund G; Lincoln K; Nilsson LG
    Eur J Clin Microbiol Infect Dis; 1990 May; 9(5):317-23. PubMed ID: 2197091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twice-daily dosing of loracarbef 200 mg versus 400 mg in the treatment of patients with acute maxillary sinusitis.
    Zeckel ML; Johns D; Masica DN; Farlow D
    Clin Ther; 1995; 17(2):214-30. PubMed ID: 7614522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefaclor advanced formulation versus cefaclor in the treatment of pneumonia.
    Casali L; Voi M; Janssen CJ; Olovich KG; Dere WH
    Clin Ther; 1992; 14(4):570-7. PubMed ID: 1525791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime.
    Cronberg S; Banke S; Bergman B; Boman H; Eilard T; Elbel E; Hugo-Persson M; Johansson E; Kuylenstierna N; Lanbeck P; Lindblom A; Paulsen O; Schönbeck C; Walder M; Wieslander P
    Scand J Infect Dis; 2001; 33(5):339-43. PubMed ID: 11440218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefprozil versus cefaclor in the treatment of acute and uncomplicated urinary tract infections. Cefprozil Multicenter Study Group.
    Iravani A; Doyle CA; Durham SJ; Wilber RB
    Clin Ther; 1992; 14(2):314-26. PubMed ID: 1611652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.